Blood pressure and cardiovascular effects of new and emerging antidiabetic agents

Current Hypertension Reports

Volumn 16, Issue 8, 2014, Pages

  Balfour, Pelbreton C ^a   Rodriguez, Carlos J ^a   Ferdinand, Keith C ^b  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antidiabetic drugs; Cardiovascular disease; Diabetes; Dipeptidyl peptidase 4 inhibitors; Glucagon like peptide 1 receptor agonists; Hypertension; Obesity; Sodium glucose cotransporter 2 inhibitors; Systolic blood pressure

Indexed keywords

ALOGLIPTIN; ANTIDIABETIC AGENT; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; SAXAGLIPTIN; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR;

BLOOD PRESSURE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; COMORBIDITY; DIABETES MELLITUS; DRUG EFFICACY; DRUG MECHANISM; GLYCEMIC CONTROL; HEART FAILURE; HUMAN; HYPERTENSION; MORBIDITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PHASE 3 CLINICAL TRIAL (TOPIC); PHASE 4 CLINICAL TRIAL (TOPIC); PREVALENCE; REVIEW; RISK FACTOR; TREATMENT OUTCOME; ANIMAL; CARDIOVASCULAR SYSTEM; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS;

ANIMALS; BLOOD PRESSURE; CARDIOVASCULAR SYSTEM; DIABETES MELLITUS, TYPE 2; HUMANS; HYPERTENSION; HYPOGLYCEMIC AGENTS; RISK FACTORS;

EID: 84901859345     PISSN: 15226417     EISSN: 15343111     Source Type: Journal    
DOI: 10.1007/s11906-014-0455-7     Document Type: Review

References (56)

1. •• Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Blaha MJ, Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Blaha MJ, Dai S, Ford ES, Fox CS, Franco S, Fullerton HJ, Gillespie C, Hailpern SM, Heit JA, Howard VJ, Huffman MD, Judd SE, Kissela BM, Kittner SJ, Lackland DT, Lichtman JH, Lisabeth LD, Mackey RH, Magid DJ, Marcus GM, Marelli A, Matchar DB, McGuire DK, Mohler ER 3rd, Moy CS, Mussolino ME, Neumar RW, Nichol G, Pandey DK, Paynter NP, Reeves MJ, Sorlie PD, Stein J, Towfighi A, Turan TN, Virani SS, Wong ND, Woo D, Turner MB. Heart disease and stroke statistics-2014 update: a report from the American Heart Association. Circulation. 2014;129(3):e28-292. This article from the American Heart Association provides the most recent data regarding cardiovascular disease morbidity and mortality.
2. Bonow RO, Gheorghiade M. The diabetes epidemic: a national and global crisis. Am J Med. 2004;116(Suppl 5A):2S-10.
3. Fox CS, Coady S, Sorlie PD, D'Agostino RBS, Pencina MJ, Vasan RS, Fox CS, Coady S, Sorlie PD, D'Agostino RB Sr, Pencina MJ, Vasan RS, Meigs JB, Levy D, Savage PJ. Increasing cardiovascular disease burden due to diabetes mellitus: the Framingham Heart Study. Circulation. 2007;115(12):1544-50. (Pubitemid 46648639)
4. Meigs JB. Epidemiology of cardiovascular complications in type 2 diabetes mellitus. Acta Diabetol. 2003;40 Suppl 2:S358-61. (Pubitemid 37549048)
5. Peters AL. Patient and treatment perspectives: Revisiting the link between type 2 diabetes, weight gain, and cardiovascular risk. Cleve Clin J Med. 2009;76 Suppl 5:S20-7.
6. Centers for Disease Control and Prevention. National diabetes fact sheet: national estimates and general information on diabetes and prediabetes in the United States, 2011. Atlanta: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention; 2011.
7. •• Eckel, R. H., Jakicic, J. M., Ard, J. D., Hubbard, V. S., de Jesus, J. M., Lee, I.-M., Yanovski, S. Z. (2013). 2013 AHA/ACC Guideline on Lifestyle Management to Reduce Cardiovascular Risk: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. This article provides very recent guidelines and supporting data regarding lifestyle management for prevention of cardiovascular disease.
8. •• James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, Lackland DT, LeFevre ML, MacKenzie TD, Ogedegbe O, Smith SC Jr, Svetkey LP, Taler SJ, Townsend RR, Wright JT Jr, Narva AS, Ortiz E. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA, J Am Med Assoc. 2014;311(5):507-20. This article provides very recent guidelines and supporting data regarding lifestyle management for prevention of cardiovascular disease.
9. Fox CS, Coady S, Sorlie PD, Levy D, Meigs JB, D'Agostino RBS, Fox CS, Coady S, Sorlie PD, Levy D, Meigs JB, D'Agostino RB Sr, Wilson PW, Savage PJ. Trends in cardiovascular complications of diabetes. JAMA, J Am Med Assoc. 2004;292(20):2495-9. (Pubitemid 39552675)
10. McFarlane SI, Sica DA, Sowers JR. Stroke in patients with diabetes and hypertension. J Clin Hypertens (Greenwich, Conn). 2005;7(5):286-92. quiz 293-294.
11. Bakris GL, Williams M, Dworkin L, Elliott WJ, Epstein M, Toto R, Bakris GL, Williams M, Dworkin L, Elliott WJ, Epstein M, Toto R, Tuttle K, Douglas J, Hsueh W, Sowers J. Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Am J Kidney Dis: Off J Natl Kidney Found. 2000;36(3):646-61.
12. US Food and Drug Administration. Guidance for Industry: Diabetes Mellitus -Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes. Food and Drug Administration, Center for Drug Evaluation and Research, December 2008. http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/ucm071627.pdf. Accessed 20 March 2014.
13. Chaggar PS, Shaw SM, Williams SG. Review article: Thiazolidinediones and heart failure. Diabetes Vascular Dis Res: Off J Int Soc Diabetes Vascular Dis. 2009;6(3):146-52.
14. •• Garber AJ, Abrahamson MJ, Barzilay JI, Blonde L, Bloomgarden ZT, Bush MA, Garber AJ, Abrahamson MJ, Barzilay JI, Blonde L, Bloomgarden ZT, Bush MA, Dagogo-Jack S, Davidson MB, Einhorn D, Garvey WT, Grunberger G, Handelsman Y, Hirsch IB, Jellinger PS, McGill JB, Mechanick JI, Rosenblit PD, Umpierrez G, Davidson MH. AACE comprehensive diabetes management algorithm 2013. Endocr Pract: Offl J Am Coll Endocrinol Am Assoc Clin Endocrinol. 2013;19(2):327-36. This document represents the most recent position statement from the American Association of Clinical Endocrinologists and the American College of Endocrinology regarding the comprehensive evaluation and management of type 2 diabetes.
15. • Fonseca VA. New developments in diabetes management: medications of the 21st century. Clin Ther. 2014;36(4):477-84. This manuscript provides a general review on new therapies for management of diabetes.
16. • Irons BK, Minze MG. Drug treatment of type 2 diabetes mellitus in patients for whom metformin is contraindicated. Diabetes, Metab Syndr Obes: Targets Ther. 2014;7:15-24. This manuscript provides a review on therapies for management of type 2 diabetes with contraindications to metformin.
17. Mann DM, Woodward M, Ye F, Krousel-Wood M, Muntner P. Trends in medication use among US adults with diabetes mellitus: glycemic control at the expense of controlling cardiovascular risk factors. Arch Intern Med. 2009;169(18):1718-20.
18. Chao EC, Henry RR. SGLT2 inhibition - a novel strategy for diabetes treatment. Nat Rev Drug Discovery. 2010;9(7):551-9.
19. • Cuypers J, Mathieu C, Benhalima K. SGLT2-inhibitors: a novel class for the treatment of type 2 diabetes introduction of SGLT2-inhibitors in clinical practice. Acta Clin Belg. 2013;68(4):287-93. This manuscript provides a focused review on sodium-glucose co-transporter inhibitors for management of diabetes.
20. • Foote C, Perkovic V, Neal B. Effects of SGLT2 inhibitors on cardiovascular outcomes. Diabetes Vascular Dis Res: Off J Int Soc Diabetes Vascular Dis. 2012;9(2):117-23. The authors provide evidence on the effects of sodium-glucose co-transporter inhibitors on the cardiometabolic risk profile of diabetics such as body weight, blood pressure and lipid levels.
21. Srinivasan BT, Jarvis J, Khunti K, Davies MJ. Recent advances in themanagement of type 2 diabetes mellitus: a review. Postgrad Med J. 2008;84(996):524-31.
22. • Vasilakou D, Karagiannis T, Athanasiadou E, Mainou M, Liakos A, Bekiari E, Vasilakou D, Karagiannis T, Athanasiadou E, Mainou M, Liakos A, Bekiari E, Sarigianni M, Matthews DR, Tsapas A. Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis. Ann Intern Med. 2013;159(4):262-74. This meta-analysis demonstrates short-term outcomes from recent clinical trials on SGLT-2 inhibitors in adults with T2DM.
23. • Valentine V. The role of the kidney and sodium-glucose cotransporter-2 inhibition in diabetes management. Clin Diabetes. 2012;30(4):151 - 5. The author provides a review of the vital role of the kidney in glucose homeostasis and importance of SGLT-2 inhibitors in management of T2DM.
24. Rahmoune H, Thompson PW, Ward JM, Smith CD, Hong G, Brown J. Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes. Diabetes. 2005;54(12):3427-34. (Pubitemid 43334332)
25. Ehrenkranz JRL, Lewis NG, Kahn CR, Roth J. Phlorizin: a review. Diabetes/Metab Res Rev. 2005;21(1):31-8.
26. • Macewen A, Mckay GA, Fisher M. Drugs for diabetes: part 8 SGLT2 inhibitors. Br J Cardiol. 2012;19(1):26-9. The article provides a brief review on recent trials of SGLT-2 inhibitors demonstrating effects on blood glucose, blood pressure and body weight.
27. • Schernthaner G, Gross JL, Rosenstock J, Guarisco M, Fu M, Yee J, Schernthaner G, Gross JL, Rosenstock J, Guarisco M, Fu M, Yee J, Kawaguchi M, Canovatchel W, Meininger G. Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control withmetformin plus sulfonylurea: a 52-week randomized trial.Diabetes Care. 2013;36(9):2508-15. The authors provide evidence from this trial that SGLT-2 inhibitors reduce hemoglobin A1C levels and body weight in patients with T2DM.
28. • Clar, C., Gill, J. A., Court, R., & Waugh, N. (2012). Systematic review of SGLT2 receptor inhibitors in dual or triple therapy in type 2 diabetes. BMJ Open, 2(5). The authors provide a review of recent evidence demonstrating overall effects of SGLT2 inhibitors on glycemic control and weight reduction.
29. Cherney DZ, Perkins BA, Soleymanlou N, Har R, Fagan N, Johansen OE, Cherney DZ, Perkins BA, Soleymanlou N, Har R, Fagan N, Johansen OE, Woerle HJ, von Eynatten M, Broedl UC. The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus. Cardiovasc Diabetol. 2014;13:13.
30. Meier JJ, Nauck MA. Glucagon-like peptide 1(GLP-1) in biology and pathology. Diabetes/Metab Res Rev. 2005;21(2):91-117. (Pubitemid 40467658)
31. • Russell-Jones D, Gough S. Recent advances in incretin-based therapies. Clin Endocrinol. 2012;77(4):489-99. The authors provide a general review on the use of incretin-based therapies such as GLP- 1 receptor agonists and DPP-4 inhibitors in the management of T2DM.
32. Vilsboll T, Krarup T, Deacon CF, Madsbad S, Holst JJ. Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients. Diabetes. 2001;50(3):609-13. (Pubitemid 32195226)
33. US Food and Drug Administration (FDA) - Byetta http://www.accessdata.fda. gov/drugsatfda-docs/label/2009/021773s9s11s18s22s25lbl.pdf. Accessed on 24 March 2014.
34. US Food and Drug Administration (FDA)-Victoza http://www.fda.gov/ newsevents/newsroom/pressannouncements/ucm198638.pdf. Accessed on 24 March 2014.
35. Shyangdan, D. S., Royle, P., Clar, C., Sharma, P., Waugh, N., & Snaith, A. (2011). Glucagon-like peptide analogues for type 2 diabetes mellitus. The Cochrane Database of Systematic Reviews, (10).
36. Nauck M, Frid A, Hermansen K, Shah NS, Tankova T, Mitha IH, et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. Diabetes Care. 2009;32(1):84-90.
37. Garber A, Henry R, Ratner R, Garcia-Hernandez PA, Rodriguez- Pattzi H, Olvera-Alvarez I, et al. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet. 2009;373(9662):473-81.
38. • Robinson, L. E., Holt, T. A., Rees, K., Randeva, H. S., & O'Hare, J. P. (2013). Effects of exenatide and liraglutide on heart rate, blood pressure and body weight: systematic review and meta-analysis. BMJ Open, 3(1). The authors provide a review of evidence demonstrating the effects of GLP-1 receptor agonists on reducing blood pressure and body weight along with increase in heart rate.
39. Pickering TG, White WB, Giles TD, Black HR, Izzo JL, Materson BJ, Pickering TG, White WB, Giles TD, Black HR, Izzo JL, Materson BJ, Oparil S, Weber MA. When and how to use self (home) and ambulatory blood pressure monitoring. J Am Soc Hypertens: JASH. 2010;4(2):56-61.
40. •• Ferdinand KC, Calhoun DA, Lonn EM, White WB, Sager P, Jiang H, Ferdinand KC, Calhoun DA, Lonn EM, White WB, Sager P, Jiang H, Threlkeld RJ. Effects of dulaglutide, a GLP-1 agonist, on ambulatory diurnal and nocturnal blood pressure in patients with type 2 diabetes [abstract]. J Clin Hypertens. 2013;15 Suppl 1:15. This abstract provides evidence from a phase 2 trial on the reduction of blood pressure with a novel GLP-1 agonist with the use of ABPM.
41. Eli Lilly and Co. Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND). clinicaltrials.gov. Bethesda (MD): National Library of Medicine; 2011-2013:NLM Identifier NCT01394952.
42. Barragan JM, Rodriguez RE, Blazquez E. Changes in arterial blood pressure and heart rate induced by glucagon-like peptide-1-(7-36) amide in rats. Am J Physiol. 1994;266(3 Pt 1):E459-66.
43. Barragan JM, Rodriguez RE, Eng J, Blazquez E. Interactions of exendin-(9-39) with the effects of glucagon-like peptide-1-(7-36) amide and of exendin-4 on arterial blood pressure and heart rate in rats. Regul Pept. 1996;67(1):63-8. (Pubitemid 26384196)
44. Isbil-Buyukcoskun N, Gulec G. Effects of intracerebroventricularly injected glucagon-like peptide-1 on cardiovascular parameters; role of central cholinergic system and vasopressin. Regul Pept. 2004;118(1-2):33-8. (Pubitemid 38167364)
45. Nystrom T, Gonon AT, Sjoholm A, Pernow J. Glucagon-like peptide-1 relaxes rat conduit arteries via an endothelium-independent mechanism. Regul Pept. 2005;125(1-3):173-7. (Pubitemid 39593722)
46. Ban K, Noyan-Ashraf MH, Hoefer J, Bolz S-S, Drucker DJ, Husain M. Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways. Circulation. 2008;117(18):2340-50. (Pubitemid 351653542)
47. •• Kim M, Platt MJ, Shibasaki T, Quaggin SE, Backx PH, Seino S, Kim M, Platt MJ, Shibasaki T, Quaggin SE, Backx PH, Seino S, Simpson JA, Drucker DJ. GLP-1 receptor activation and Epac2 link atrial natriuretic peptide secretion to control of blood pressure. Nat Med. 2013;19(5):567-75. This article provides evidence using animal models on the anti-hypertensive effects of GLP-1 receptor agonists.
48. Food and Drug Administration. FDA Announces New Recommendations on Evaluating Cardiovascular Risk in Drugs Intended to Treat Type 2 Diabetes. http://www.fda.gov/Newsevents/Newsroom/PressAnnouncements/2008/ucm116994.htm. Accessed 24 March 2014.
49. •• Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, Ohman P, Frederich R, Wiviott SD, Hoffman EB, Cavender MA, Udell JA, Desai NR, Mosenzon O, McGuire DK, Ray KK, Leiter LA, Raz I. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013;369(14):1317-26. This manuscript provides data regarding CVD outcomes with Saxagliptin (DPP-4 inhibitor) and suggests potential link with increased heart failure events prompting further investigation by the FDA.
50. •• White WB, Cannon CP, Heller SR, Nissen SE, Bergenstal RM, Bakris GL, White WB, Cannon CP, Heller SR, Nissen SE, Bergenstal RM, Bakris GL, Perez AT, Fleck PR, Mehta CR, Kupfer S, Wilson C, Cushman WC, Zannad F. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. Engl J Med. 2013;369(14):1327-35. This manuscript provides data demonstrating no increased CVD events with alogliptin (DPP-4 inhibitor) in adults with T2DM.
51. Food and Drug Administration. FDA Drug Safety Communication: FDA to review heart failure risk with diabetes drug saxagliptin (marketed as Onglyza and Kombiglyze XR). http://www.fda.gov/Drugs/DrugSafety/ucm385287.htm. Accessed 24 March 2014.
52. Kannel WB, Hjortland M, Castelli WP. Role of diabetes in congestive heart failure: the Framingham study. AmJ Cardiol. 1974;34(1):29-34.
53. Bibbins-Domingo K, Lin F, Vittinghoff E, Barrett-Connor E, Hulley SB, Grady D, Bibbins-Domingo K, Lin F, Vittinghoff E, Barrett-Connor E, Hulley SB, Grady D, and Shlipak MG. Predictors of heart failure among women with coronary disease. Circulation. 2004;110(11):1424-30. (Pubitemid 39263737)
54. Bertoni AG, Goff DCJ, D'Agostino RBJ, Liu K, Hundley WG, Lima JA, Bertoni AG, Goff DC Jr, D'Agostino RB Jr, Liu K, Hundley WG, Lima JA, Polak JF, Saad MF, Szklo M, Tracy RP, Siscovick DS. Diabetic cardiomyopathy and subclinical cardiovascular disease: the Multi-Ethnic Study of Atherosclerosis (MESA). Diabetes Care. 2006;29(3):588-94. (Pubitemid 44115359)
55. Bertoni AG, Hundley WG, Massing MW, Bonds DE, Burke GL, Goff DCJ. Heart failure prevalence, incidence, and mortality in the elderly with diabetes. Diabetes Care. 2004;27(3):699-703. (Pubitemid 38280536)
56. Devereux RB, Roman MJ, Paranicas M, O'Grady MJ, Lee ET, Welty TK, Devereux RB, Roman MJ, Paranicas M, O'Grady MJ, Lee ET, Welty TK, Fabsitz RR, Robbins D, Rhoades ER, Howard BV. Impact of diabetes on cardiac structure and function: the strong heart study. Circulation. 2000;101(19):2271-6. (Pubitemid 30317129)